Louis Stokes Veteran Affairs Medical Center, Cleveland, OH, USA.
Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Eur J Heart Fail. 2022 Aug;24(8):1427-1438. doi: 10.1002/ejhf.2446. Epub 2022 Mar 10.
Despite the common occurrence of coronary artery disease (CAD) and heart failure (HF) with preserved ejection fraction (HFpEF), there is limited evidence to guide revascularization.
We investigated the long-term outcomes of coronary artery bypass grafting (CABG) in patients with HF and significant CAD across the spectrum of ejection fraction, using a large national cohort of patients from the Veteran Affairs (VA) Medical Centers in the US. Patients with HF were stratified into groups, HFpEF, HF with mid-range ejection fraction (HFmrEF), and HF with reduced ejection fraction (HFrEF) and compared to patients with no preoperative HF. We analysed 10 396 patients. Despite an increased hazard in the first year following revascularization, the long-term survival (median follow-up 6.6 years; interquartile range 3.7-10.1) of HFpEF post-CABG was similar to controls (hazard ratio 0.85, 95% confidence interval 0.68-1.06), but survival progressively declined with HFmrEF and HFrEF. Similar trends were seen with recurrent HF hospitalization with lower risk with baseline HFpEF (43.9 ± 6.9/100 patient-years) compared to HFmrEF (65.9 ± 3.8/100 patient-years) and HFrEF (93.4 ± 4.8/100 patient-years). Although HFpEF patients had lower mortality and HF hospitalization post-CABG compared to patients with a lower ejection fraction, they experienced the highest rates of future myocardial infarction.
Although HFpEF patients with CAD have greater short-term risk post-CABG, their long-term survival is comparable to controls. However, they are at increased risk for HF hospitalizations and myocardial infarction. These data support the safety of CABG in HFpEF patients and suggest continuum of mortality risk for ischaemic HF when stratified by baseline ejection fraction before revascularization.
尽管冠状动脉疾病 (CAD) 和射血分数保留型心力衰竭 (HFpEF) 同时存在较为常见,但针对这一病症的血运重建治疗仍缺乏充分的证据。
我们利用美国退伍军人事务部 (VA) 医疗中心的大型全国患者队列,研究了在射血分数谱范围内 CAD 合并 HF 患者接受冠状动脉旁路移植术 (CABG) 的长期预后。将 HF 患者分为 HFpEF、射血分数中间值 HF (HFmrEF) 和射血分数降低型 HF (HFrEF) 亚组,并与无术前 HF 的患者进行比较。共分析了 10396 例患者。尽管 CABG 后第一年的死亡风险增加,但 HFpEF 患者的长期生存率(中位随访时间 6.6 年;四分位间距 3.7-10.1)与对照组相似(风险比 0.85,95%置信区间 0.68-1.06),但 HFmrEF 和 HFrEF 患者的生存率逐渐下降。HF 再住院率也呈现类似趋势,基线时 HFpEF 患者的风险较低(43.9±6.9/100 患者年),低于 HFmrEF(65.9±3.8/100 患者年)和 HFrEF(93.4±4.8/100 患者年)。尽管 CABG 后 HFpEF 患者的死亡率和 HF 住院率低于射血分数较低的患者,但他们发生未来心肌梗死的风险最高。
尽管 CAD 合并 HFpEF 患者 CABG 术后短期内风险较高,但长期生存率与对照组相当。然而,他们发生 HF 住院和心肌梗死的风险增加。这些数据支持 CABG 在 HFpEF 患者中的安全性,并提示在血运重建前根据基线射血分数分层,缺血性 HF 的死亡风险呈连续变化。